Signal #134605 · SEC 8-K

$MLYS SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $MLYS filing catalyst

Why did $MLYS trigger an AI stock catalyst alert?

$MLYS triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.5/10). Headline: Mineralys Therapeutics Reports Q3 Net Loss of $57.3M ($0.64/Share). Key points: - Q3 net loss expanded to $57.3 million ($0.64 per share) vs. $36.9 million ($0.52 per share) in Q3 2025. - Operating expenses rose to $60.1 million driven by higher G&A costs, partially offset by reduced R&D. - Commercialization plans for lorundrostat remain on track ahead of the December 22, 2026 PDUFA target date.

How did $MLYS stock react after the SEC filing?

After the SEC 8-K for $MLYS, observed market reaction: T0 price $17.00. Past moves do not guarantee future results.

Where can I get real-time $MLYS SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $MLYS via Telegram and the VIP Web Terminal from €10/month.

$MLYS

$MLYS – Mineralys Therapeutics Reports Q3 Net Loss of $57.3M ($0.64/Share)

Mineralys Therapeutics, Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $MLYS

Unlocked archive · Analyzed in <2s at T0

Bearish AI Sentiment (-1.5 / 10)

Q3 net loss expanded to $57.3 million ($0.64 per share) vs. $36.9 million ($0.52 per share) in Q3 2025.
Operating expenses rose to $60.1 million driven by higher G&A costs, partially offset by reduced R&D.
Commercialization plans for lorundrostat remain on track ahead of the December 22, 2026 PDUFA target date.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →